MGWM
GMAB icon

Marks Group Wealth Management’s Genmab GMAB Stock Holding History

Marks Group Wealth Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,954
Closed -$267K – 292
2024
Q3 		$267K Sell
10,954
-26
-0.2% -$695 0.03% 266
2024
Q2 		$276K Sell
10,980
-902
-8% -$25.6K 0.03% 265
2024
Q1 		$355K Sell
11,882
-29
-0.2% -$852 0.04% 245
2023
Q4 		$379K Sell
11,911
-858
-7% -$26.9K 0.04% 236
2023
Q3 		$450K Buy
+12,769
New +$487K 0.06% 214

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Marks Group Wealth Management's GMAB Position: Q4 2024 in Review

Marks Group Wealth Management sold out of Genmab (GMAB) in Q4 2024, closing a stake of 10,954 shares — an estimated $267K sold.

Marks Group Wealth Management first reported a position in GMAB in Q3 2023 and held it in 5 quarters. The position peaked at $450K in Q3 2023. 228 funds tracked by Wall St. Rank hold GMAB as of Q4 2024.

  • Marks Group Wealth Management reported no remaining Genmab position as of Q4 2024 after selling out during the quarter.
  • Marks Group Wealth Management sold 10,954 Genmab shares in Q4 2024, an estimated $267K.
  • Marks Group Wealth Management first reported a position in Genmab in Q3 2023 and held it in 5 quarters.
  • Marks Group Wealth Management's Genmab position peaked at $450K in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Genmab as of Q4 2024.

Based on Marks Group Wealth Management's 13F filing for Q4 2024, filed 29 Jan 2025.